Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
about
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Research progress of neuroblastoma related gene variations.Recent insights into the biology of neuroblastoma.Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
P2860
Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical characteristics and o ...... ation of loci other than MYCN.
@ast
Clinical characteristics and o ...... ation of loci other than MYCN.
@en
type
label
Clinical characteristics and o ...... ation of loci other than MYCN.
@ast
Clinical characteristics and o ...... ation of loci other than MYCN.
@en
prefLabel
Clinical characteristics and o ...... ation of loci other than MYCN.
@ast
Clinical characteristics and o ...... ation of loci other than MYCN.
@en
P2093
P2860
P50
P1433
P1476
Clinical characteristics and o ...... ation of loci other than MYCN.
@en
P2093
Carole Coze
Dominique Plantaz
Estelle Thebaud
Eve Lapouble
Gaëlle Pierron
Gudrun Schleiermacher
Jean Michon
Jérôme Couturier
Marion Gambart
Michel Peuchmaur
P2860
P304
P356
10.1371/JOURNAL.PONE.0101990
P407
P577
2014-07-11T00:00:00Z